# Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

> **NCT00947544** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 17 (actual)

## Conditions studied

- Urea Cycle Disorders

## Interventions

- **DRUG:** HPN-100
- **DRUG:** NaPBA

## Key facts

- **NCT ID:** NCT00947544
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00947544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00947544, "Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00947544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*